# Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND

> **NCT02870634** · PHASE1 · COMPLETED · sponsor: **Collaborative Medicinal Development Pty Limited** · enrollment: 50 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- Motor Neuron Disease

## Interventions

- **DRUG:** Cu(II)ATSM

## Key facts

- **NCT ID:** NCT02870634
- **Lead sponsor:** Collaborative Medicinal Development Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-16
- **Primary completion:** 2019-10-30
- **Final completion:** 2020-01-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02870634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02870634, "Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02870634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*